| | |
| |  | SEPTEMBER 2, 2020
Vaccine Front-Runner Now First to Enter Final Clinical Trials
Dear The Startup Investor Reader,
Biotech expert Michael Robinson has been tracking what he calls a viable "Super Vaccine" for COVID-19.
And the company behind it just posted a stunning announcement.
JUST IN: This "Super Vaccine" just became the FIRST to enter the final phase of clinical trials.
That means the company is expected to announce results in the next few weeks.
And so far, their vaccine has generated positive immune response in 100% of humans in trials.
The U.S. government has already signed a $1.5 BILLION deal with this company.
The production of millions of doses is underway.
And the next few weeks could be huge for anyone holding this stock.
Before this could rocket out of reach, click here to see Michael's take.
Sincerely,
Bob Keppel
Publisher, The Startup Investor | Please do not reply to this email. It was sent from an unmonitored mailbox.
You are receiving this e-mail at phanphuongthanh89.822152@blogger.com, as part of your subscription to The Startup Investor. To remove your email from this list: unsubscribe here.
To cancel, or for any other questions or requests, please contact our Customer Service team:
Online
Phone: 866-310-1498 (North America) 443-221-6766 (International)
Mail: The Startup Investor | Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201
Our Customer Service team is available Monday ‑ Friday between 9:00 AM and 5:00 PM ET.
© 2020 Angels & Entrepreneurs. All Rights Reserved.
Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice.
We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.
Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Angels & Entrepreneurs. 1125 N Charles Street, Baltimore, MD 21201.
Website | Privacy Policy | Terms & Conditionshttp://link.e.angelsandentrepreneurs.com/wf/unsubscribe?upn=SVR9z3LgXEwEIVbUkFIuhfIKPV96lSE9UseWeXZ52MI4WY4eEn-2FXQBTN4MGeOz0GseIyndgO8daCHIwjmPi0EySCaAsypuV8RNEMBC-2FVlkhIHWMm1hw0uSXu4GkwGu9TAayNV8TQjBBSMH1t8f3YsH-2BEq2eiGipWZqe-2B8-2FM83BW0PLWRHvzNABv2mbfX6aOkYd2RX8zhEHaFWE1Vt-2Bnb2jkGzTfm3Z7XUvNvBbxbVPokjpnzO0W5DoraexcOaIk-2B-2BdmKcuxHHs4GYChUzZ4nKlIS4xmjLgqp2ddlCumNuBa9WHDtL05PFswp-2FzSDtLUpBpG1soNF55-2FLn29aWThcPdyKaEkJpff58pYPby3Zwsdq8pty4jxpe8DVxzFRqfJZBNjNM0EeCkWQ64oWvU77WL2NLRZUWaG0Cdjqwn0aNmGtCTbGOc7osUObGQa8n5vjjz83amhVW6oSJEktX7GPcZ2PwaToa-2B32L3e-2Fj8DNMKzM18eF-2F835rApX4uhFZ-2Bgy8l1tJ7giJGJUbildjnXgkqVcl-2BQIFvUBY6kNFJtYjPMkH7ZHV7Qo6fTcz7iOmt75BsmeIxUm35cYJti2DAsLJ152jQDrYjAplHKLnrcf4vkpFkHKO8tktjiXcPLEICEWzHj3XB9pfYiz9GWmevZq5l3upnlqllQnZg7NThT9dEJvRT-2BvughYiCLU7098-2B6pCrgJfTu0TpD-2BxnNo6lxflRomn-2FOqGc67e2J2QcMwBVdbmlZ9anDXzg8G3MY5wLnvvquiba4gx0qsqUSxRvsBe2tO9aaYNNyUuh1m-2BFR6Y7HrwndzhuXriXC68zmbh5HgOlA5hDDJZpBiU9Xj7kQlt3ZPDJmKFp-2FQc6SiTDhNJTpx1kgEE7iY50QaMvmrHnBQAWrIYDr0UDWgJkOcwd0hQkN1LIxImHhN8Vhv-2F0QVRLnjkrHrl96fHstzqWios0g1U04BG8jpW7blFDRLX2UcX23T8TEWaREMUpislhS8j-2FT-2FOeZ7eXQjTv4i8A1yRopsvbj0uYay2HVYXFagFQky4pB49ZAZgAO4qlMA-2BZZpwQGI-3D |
|
No comments:
Post a Comment